Syngeneic tumor mouse models

CG Christophe Glorieux
XX Xiaojun Xia
XY Xin You
ZW Zining Wang
YH Yi Han
JY Jing Yang
GN Gauthier Noppe
CM Christophe de Meester
JL Jianhua Ling
AR Annie Robert
HZ Hui Zhang
SL Sheng-Ping Li
HW Huamin Wang
PC Paul J. Chiao
LZ Li Zhang
XL Xiaobing Li
PH Peng Huang
ask Ask a question
Favorite

Cohorts of 6–7 weeks old female black C57BL/6, white BALB/c, or nude BALB/c mice were purchased from Vital River Laboratory Animal Technology (Beijing, China). Mice were first kept for an acclimation period of 7–14 days in a controlled pathogen-free environment before study began. Mouse KPC pancreatic cancer cells (1-2x106) or CT26 colon cancer cells (0.3x106) were injected into the right flanks of the 7–8 weeks old mice. Before drug administration, mice were randomly divided into the indicated groups without blinding. For drug treatment, anti-mouse PD-1 antibody (BioXcell, West Lebanon, NH, USA; #BE0146), cisplatin (Hospira, Lake Forest, IL, USA; CAS 15663-27-1), and gemcitabine (Eli Lilly and Company, Indianapolis, IN, USA; CAS 122111-03-9) were administrated twice a week for 3 weeks as indicated. Body weights and tumor volumes were measured twice per week. Tumor volume was calculated using the following formula: tumor volume (mm3) = (length (mm) × width2 (mm))/2. Moribund mice or animals with tumors of greater than 15 mm in length or with ulcerated tumors were promptly sacrificed to avoid unnecessary pain and suffering.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A